Progenics Pharmaceuticals is an oncology company focused on the development and commercialization of medicines and artificial intelligence to find, fight and follow cancer. Co.'s product candidates include: AZEDRA® (iobenguane I 131), which is a radiotherapeutic for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy; and 1095, which is a prostate-specific membrane antigen-targeted iodine-131 labeled small molecule that is designed to deliver a dose of beta radiation directly to prostate cancer cells with minimal impact on the surrounding healthy tissues. The PGNX stock yearly return is shown above.
The yearly return on the PGNX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PGNX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|